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from a large commercial administrative claims database were classiﬁed as initiators of 
duloxetine (n = 7,567), venlafaxine XR (n = 6106), escitalopram (n = 10,239), or 
generic SSRIs (n = 20,114) during the calendar year 2006. Patients who had used the 
same antidepressant in the 3 months prior to initiation date were excluded. Adherence 
was deﬁned as the medication possession ratio (MPR) ≥0.8, and persistence was 
deﬁned as the length of therapy without exceeding a 15-day gap in the post 1 year. 
Pair-wise comparisons were performed with and without adjustment for demographic 
and clinical covariates. RESULTS: Adherence rate in the post 1 year was signiﬁcantly 
higher in duloxetine recipients (38.1%) than those patients treated with venlafaxine 
XR (34.0%), escitalopram (25.4%), or generic SSRIs (25.5%) (all p values < .01). 
Duloxetine recipients stayed on the medication longer (158.5 days) than those who 
received venlafaxine XR (149.6 days), escitalopram (129.1 days), or generic SSRIs 
(130.2 days) (all p values < 0.01). Compared with patients treated with escitalopram 
or generic SSRIs, venlafaxine XR recipients had better adherence and longer persis-
tence (p < 0.01). After adjustment for baseline demographics, prior medications, and 
comorbid conditions, duloxetine still had better adherence and longer persistence than 
venlafaxine XR, with escitalopram and generic SSRIs having lower adherence and 
persistence. CONCLUSIONS: Duloxetine-treated patients may have better adherence 
and longer stay on the medication than those patients treated with venlaxaﬁne XR, 
escitalopram, or generic SSRIs. Further research is needed to examine clinical and 
economical beneﬁts of adherence and persistence with antidepressant therapy.
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OBJECTIVES: Antipsychotic non-adherence has been associated with poor health 
outcomes in patients with chronic comorbid conditions. We explored the relationship 
between antipsychotic adherence and adherence with medications for chronic comor-
bid illness in the North Carolina Medicaid program. METHODS: Medicaid claims 
were used to identify continuously enrolled patients with schizophrenia from 2001–
2003. The annual prevalence of comorbid diabetes, hyperlipidemia, and hypertension 
was evaluated among these patients. The relationship of antipsychotic adherence with 
comorbid medication adherence was examined descriptively using the proportion of 
days covered (PDC). In addition, patients with comorbid illness who experienced a 
90 day gap in antipsychotic treatment were compared to patients without a 90 day 
gap. Difference-in-difference regression was used to compare comorbid medication 
adherence 10 months pre- and post-antipsychotic gap between patients with and 
without a 90 day antipsychotic treatment gap. RESULTS: Of the 6841 continuously 
enrolled Medicaid patients identiﬁed with schizophrenia in 2001, the prevalence of 
comorbid hypertension, hyperlipidemia, and diabetes was 13.9%, 16.6%, and 18.9% 
respectively in 2002 and 15.3%, 20.0%, and 21.0% respectively in 2003. Descriptive 
trends suggested a correlation between antipsychotic and chronic comorbid medica-
tion adherence. Patients with a 90 day antipsychotic gap experienced a decline in 
adherence to comorbid medication following the gap. In comparison to patients 
without a gap, patients who discontinued antipsychotic treatment for 90 days or more 
experienced a 4.5% [95% Conﬁdence Interval: (−16.0, 7.1)], 1.5% (−8.6, −0.04) 
reduction in antihypertensive, antihyperlipidemic, and antidiabetic PDC respectively 
following the gap. CONCLUSIONS: While non-adherence is a behavioral phenome-
non affecting both the treatment of schizophrenia and comorbid conditions, we 
observed an incrementally larger decline in comorbid medication adherence among 
patients with antipsychotic treatment gaps. Larger sample sizes, additional control for 
confounding, and assessment of corresponding health outcome measures are needed 
to further explore the magnitude of this problem.
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OBJECTIVES: The Texas DMIE study examines whether participants with potentially 
disabling physical and/or behavioral conditions receiving a coordinated set of health 
and employment supports can avoid dependence on federal disability beneﬁts. This 
study examines differences in antidepressant adherence and persistence between inter-
vention and control participants enrolled in the Texas DMIE study. METHODS: 
DMIE is a randomized controlled trial with 1616 participants aged 21–60; working 
a minimum average of 40 hours per month; diagnosed with behavioral health and/or 
physical health conditions; and who are not currently receiving disability. A subgroup 
with a major depression diagnosis and prescribed antidepressant medication 
12-months prior and 12-months post enrollment was examined. Drug adherence was 
measured using proportion of days covered (PDC) for each patient during the 365-day 
pre- and post-enrollment observation periods. Medication persistence measured the 
duration of time from initiation to discontinuation of antidepressants based on a ≥ 
35-day reﬁll supply gap. Covariates included overall health morbidity, age, race/eth-
nicity, gender, occupation, serious mental illness status, and recruitment method (mail/
telephone versus in-person). Findings were based on analysis of covariance for adher-
ence and survival analysis for persistence. RESULTS: This study sample included 166 
DMIE participants (Intervention n = 101 and Control n = 65), with a mean age of 
47.8 years. The model showed (F[1148] = 4.47, p < 0.05) intervention participants 
recruited in-person at community health clinics with a higher mean PDC (70%) 
compared with control group participants (54%). Variation in persistence were 
statistically signiﬁcant among older (HR = .97, p < 0.05) and higher education 
(HR = .71, p < 0.01) participants, however, group differences were not found between 
the cohorts. CONCLUSIONS: Adherence rates differed between intervention and 
control based on recruitment cohort which may reﬂect lower motivation level on the 
mail/telephone recruited participants. Findings may help guide implementation of 
health care reform targeted toward low-income working adults lacking health 
insurance.
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OBJECTIVES: Despite the availability of highly efﬁcacious treatment options for 
Opioid addicted patients, these patients often suffer from poor outcomes due to low 
rate of compliance. To improve compliance and achieve better health outcomes we 
developed a patient supported system that assisted patients with drug information, 
training and timely reminders. METHODS: The current compliance rates were 
reviewed using published literature. Information on standard of care was collected 
from prescribers and treatment centers. 2000 patients were enrolled 50:50 in study 
and control arm. Duration of study was six months. The data for number of missed 
appointments, prescription reﬁlls and health outcomes were collected from both arms. 
A comparative analysis was used to determined a need for additional treatment 
support RESULTS: The support system provided telephonic support and care coach-
ing to opioid addicted patients. Trained staff of RN’s and CDC’s were able to discuss 
treatment, disease and other issues in an effort to keep patients compliant and on 
therapy. As compared to the control arm, patients in the study arm stayed on therapy 
for an additional average 3 months. This support system reduced the need for ancillary 
support and led to 30% cost savings for the system. CONCLUSIONS: Patient support 
systems can signiﬁcantly improve patient compliance by providing support, training 
and reminders to patients. Such programs also provide valuable “real world” data 
and save costs for treating patients. Results of this program demonstrate that it is 
more cost effective for payers to pay for additional levels of drug therapy than to treat 
patients for relapse in other care settings.
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OBJECTIVES: Approved treatments in Canada for attention-deﬁcit/hyperactivity dis-
order (ADHD) include three classes of drugs: short-acting (SA) and long-acting (LA) 
stimulants and a LA nonstimulant medication. Since ADHD is a chronic condition 
requiring continuing treatment, compliance to the treatment regimen is important. The 
objectives of this study were to estimate adherence and persistence to ADHD treat-
ments. METHODS: A retrospective prescription claims analysis of a random sample 
of 15,838 ADHD patients from the Quebec provincial health plan (RAMQ) database 
was conducted. Patients with ≥1 physician claim with a diagnosis of ADHD and a 
drug claim for a treatment approved for ADHD from July 2004 to June 2009 were 
considered. Only those patients with no prescription claim in the 3 months prior to 
the index date (date of ﬁrst prescription ﬁll) were eligible for inclusion in the analysis. 
Treatment compliance was estimated using medication possession ratio over a one-
year period. Patients were considered nonpersistent if they had not used the ADHD 
medication for a period of at least 3 months. Proportion of patients who were persis-
tent was estimated at 3, 6, and 12 months after index prescription. RESULTS: The 
mean age of the study sample was 14.0 years (SD = 8) and 72.6% were males. The 
proportion of patients who were ≥80% compliant on SA stimulants (39.4%) was 
lower compared with LA stimulants (63%, p < 0.001) and LA nonstimulants (60.2%, 
p < 0.001). The proportion of patients who were persistent on LA stimulants (81.1%) 
at 12 months was higher when compared with those on LA nonstimulants (61.7%; p 
< 0.001) and SA stimulants (59.6%; p < 0.001). Similar trends were observed at all 
time points examined.CONCLUSIONS: Results of these prescription claims analyses 
indicate that adherence to ADHD treatments is poor, however improved adherence 
and persistence are observed with LA stimulant formulations. Supported by funding 
from Shire Development Inc.
